A Phase IIIb, Multicentre, Interventional, Randomised, Placebo-Controlled Clinical Trial Investigating the Efficacy and Safety of Guselkumab for the Treatment of Nonpustular Palmoplantar Psoriasis (G-PLUS)

<div>Pharmacodynamic effects on IL-17A, IL-17F, and IL-22 are different for guselkumab and placebo groups at week 16. CI, confidence interval; GUS, guselkumab; IL, interleukin; LS, least squares; PBO, placebo; PD, pharmacodynamic; W, week.</div>

Dermatologic Therapy

fig5

Figure 5

Figure 5: A Phase IIIb, Multicentre, Interventional, Randomised, Placebo-Controlled Clinical Trial Investigating the Efficacy and Safety of Guselkumab for the Treatment of Nonpustular Palmoplantar Psoriasis (G-PLUS) 

Figure 5 | A Phase IIIb, Multicentre, Interventional, Randomised, Placebo-Controlled Clinical Trial Investigating the Efficacy and Safety of Guselkumab for the Treatment of Nonpustular Palmoplantar Psoriasis (G-PLUS) 